Suppressive Treatment for HSV-1
For recurrent HSV-1 infection requiring suppression, use acyclovir 400 mg orally twice daily, or alternatively valacyclovir 500 mg once daily or famciclovir 250 mg twice daily. These regimens reduce recurrence frequency by at least 75% in patients with frequent outbreaks (≥6 episodes per year) 1.
Who Should Receive Suppressive Therapy
Suppressive therapy is indicated for patients experiencing:
- Six or more recurrences per year (the threshold established in guidelines) 2, 1
- Significant quality of life impairment from recurrent episodes
- Desire to reduce transmission risk to partners
Recommended Regimens
First-Line Options
Acyclovir:
- 400 mg orally twice daily 1
- Alternative: 200 mg orally 3-5 times daily (to identify the lowest effective dose for each patient) 2
- Safety and efficacy documented for up to 6 years of continuous use 1
Valacyclovir:
- 500 mg once daily (standard dose) 1
- 250 mg twice daily or 1000 mg once daily (alternatives) 1
- Important caveat: 500 mg once daily appears less effective in patients with ≥10 recurrences per year; use higher doses for these patients 1
Famciclovir:
Comparative Effectiveness
The 1998 CDC guidelines indicate that valacyclovir and famciclovir are comparable to acyclovir in clinical outcomes 1. Network meta-analysis shows no clear superiority of one drug over another 3. However, valacyclovir and famciclovir offer more convenient dosing schedules, which is clinically important for long-term adherence 1.
Research data supports high efficacy:
- Acyclovir 400 mg twice daily: 53% reduction in clinical recurrences 4
- Valacyclovir 500 mg once daily: 69% remained recurrence-free at 16 weeks 5
- All three agents show >75% reduction in recurrence frequency 1, 3
Duration and Monitoring
After 1 year of continuous suppressive therapy, discontinue treatment to reassess the patient's recurrence rate 2, 1. This is critical because:
- Recurrence frequency naturally decreases over time in many patients 1
- Allows assessment of psychological adjustment to the condition 1
- Determines ongoing need for suppression
Important Clinical Considerations
Resistance concerns are minimal:
- Acyclovir-resistant strains have been isolated but are not associated with treatment failure in immunocompetent patients 2
- Resistance rates remain <0.5% in immunocompetent hosts 6
- Long-term suppressive therapy (up to 6 years with acyclovir) has not been associated with clinically significant resistance emergence 1
Transmission risk:
- Suppressive therapy reduces but does not eliminate asymptomatic viral shedding 2, 1
- The extent to which suppression prevents transmission is unknown 1
- Counsel patients to use condoms during all sexual exposures 2
Special Populations
Immunocompromised patients:
- May require more aggressive therapy 2
- Higher risk of acyclovir resistance (7% vs <0.5%) 6
- Consider alternative antiviral agents if resistance develops 2
Patients with very frequent recurrences (≥10/year):
- Avoid valacyclovir 500 mg once daily 1
- Use valacyclovir 1000 mg once daily, 250 mg twice daily, or famciclovir 250 mg twice daily 1
Practical Algorithm
- Confirm frequent recurrences: Document ≥6 episodes per year
- Choose initial regimen based on convenience:
- Once-daily dosing preferred: Valacyclovir 500 mg daily (if <10 recurrences/year) or 1000 mg daily (if ≥10 recurrences/year)
- Twice-daily dosing: Acyclovir 400 mg twice daily or famciclovir 250 mg twice daily
- Reassess at 1 year: Discontinue therapy to evaluate ongoing need
- Resume if needed: Based on recurrence pattern after discontinuation